- ►diabetesjournals.org [PDF] G Xu, DA Stoffers, JF Habener, S Bonner-Weir - Diabetes, 1999 - Am Diabetes Assoc Diabetes is a disease of increasing prevalence in the general population and of
unknown cause. Diabetes is manifested as hyperglycemia due to a relative defi-
ciency of the production of insulin by the pancreatic -cells. One ... Cited by 514 - Related articles - All 4 versions
- ►diabetesjournals.org [PDF] DA Stoffers, TJ Kieffer, MA Hussain, DJ … - Diabetes, 2000 - Am Diabetes Assoc Diabetes is caused by a failure of the pancreas to pro- duce insulin in amounts
sufficient to meet the body's needs. A hallmark of diabetes is an absolute (type
1) or relative (type 2) reduction in the mass of pancreatic ß-cells that ... Cited by 338 - Related articles - BL Direct - All 4 versions
J Zhou, X Wang, MA Pineyro, JM Egan - DIABETES-NEW YORK-, 1999 - Am Diabetes Assoc In this article, we show that glucagon-like peptide 1 (GLP-1) can induce AR42J
cells to differentiate into insulin, pancreatic polypeptide, and
glucagon-positive cells. In their natural state, these cells, which are ... Cited by 236 - Related articles - BL Direct - All 4 versions
G Xu, DA Stoffers, JF Habener, S Bonner-Weir - DIABETES-NEW YORK-, 1999 - Am Diabetes Assoc Diabetes is a disease of increasing prevalence in the general population and of
unknown cause. Diabetes is manifested as hyperglycemia due to a relative defi-
ciency of the production of insulin by the pancreatic -cells. One ... Cited by 133 - Related articles - BL Direct
- ►diabetesjournals.org C Tourrel, D Bailbé, MJ Meile, M Kergoat, B … - Diabetes, 2001 - Am Diabetes Assoc In neonatal Wistar rats injected with streptozotocin (STZ) at birth (n0-STZ
model), a recognized model of β-cell regeneration, we investigated the capacity
of early treatment with glucagon-like peptide 1 (GLP-1) or exendin-4 to ... Cited by 171 - Related articles - BL Direct - All 5 versions
- ►glucagon.com [PDF] Y Li, T Hansotia, B Yusta, F Ris, PA Halban, … - Journal of Biological Chemistry, 2003 - ASBMB Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β
cell mass via activation of β cell proliferation and islet neogenesis. We
examined whether GLP-1 receptor signaling modifies the cellular ... Cited by 252 - Related articles - BL Direct - All 7 versions
- ►endojournals.org R Perfetti, J Zhou, ME Doyle, JM Egan - Endocrinology, 2000 - Endocrine Soc Glucose homeostasis in mammals is maintained by insulin secretion from the
ß-cells of the islets of Langerhans. Type 2 diabetes results either from
primary ß-cell failure alone and/or a failure to secrete enough insulin to ... Cited by 191 - Related articles - BL Direct - All 3 versions
M Zander, S Madsbad, JL Madsen, JJ Holst - The Lancet, 2002 - Elsevier 20 patients with type 2 diabetes were alternately assigned continuous
subcutaneous infusion of GLP-1 (n=10) or saline (n=10) for 6 weeks. Before (week
0) and at weeks 1 and 6, they underwent β-cell function tests ... Cited by 615 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org C Tourrel, D Bailbe, M Lacorne, MJ Meile, M … - Diabetes, 2002 - Am Diabetes Assoc In the Goto-Kakizaki (GK) rat, a genetic model of type 2 diabetes, the neonatal
β-cell mass deficit is considered to be the primary defect leading to basal
hyperglycemia, which is detectable for the first time 3 weeks after birth. ... Cited by 151 - Related articles - BL Direct - All 4 versions
MA Nauck, N Kleine, C Ørskov, JJ Holst, B … - Diabetologia, 1993 - Springer Summary. Glucagon-like peptide I (GLP-1) (7-36 amide) is a physiological
incretin hormone that is released after nutrient intake from the lower gut and
stimulates insulin secretion at elevated plasma glucose concentrations. ... Cited by 426 - Related articles - BL Direct - All 6 versions
